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Abstract
Background: Infections caused by multiply drug resistant organisms such as extended spectrum
beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae are increasing.
Carbapenems (imipenem and meropenem) are the antibiotics commonly used to treat these
agents. There is limited clinical data regarding the efficacy of the newest carbapenem, ertapenem,
against these organisms. Ertapenem susceptibility of ESBL-producing E. coli and K. pneumoniae
clinical isolates were evaluated and compared to imipenem to determine if imipenem susceptibility
could be used as a surrogate for ertapenem susceptibility.
Methods: 100 ESBL isolates (n = 34 E. coli and n = 66 K. pneumoniae) collected from 2005–2006
clinical specimens at WRAMC were identified and tested for susceptibility by Vitek Legacy
[bioMerieux, Durham, NC]. Ertapenem susceptibility was performed via epsilometer test (E-test)
[AB Biodisk, Solna, Sweden].
Results: 100% of ESBL isolates tested were susceptible to ertapenem. 100% of the same isolates
were also susceptible to imipenem.
Conclusion: These results, based on 100% susceptibility, suggest that ertapenem may be an
alternative to other carbapenems for the treatment of infections caused by ESBL-producing E. coli
and K. pneumoniae. Clinical outcomes studies are needed to determine if ertapenem is effective for
the treatment of infection caused by these organisms. However, due to lack of resistant isolates,
we are unable to conclude whether imipenem susceptibility accurately predicts ertapenem
susceptibility.
Background
Military operations in Southwest Asia have led to an
increase in patients at Walter Reed Army Medical Center
(WRAMC) admitted with traumatic injury and compli-
cated infections caused by multiply drug resistant organ-
isms such as extended spectrum beta-lactamase (ESBL)-
producing Escherichia coli and Klebsiella pneumoniae [1].
Outpatient antibiotic regimens for the war wounded have
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organisms. Mortality from infections caused by these
organisms may range from 42–100% if not treated with
appropriate antibiotics [2]. Carbapenems [imipenem
(IPM) and meropenem (MEM)] are the drugs of choice to
treat infection caused by ESBL-producing organisms [2-5].
However, the multiple daily dosing required for these
antibiotics make them an onerous treatment regimen for
soldiers once they have left the hospital.
There is limited clinical data regarding ertapenem (ETP),
a relatively new carbapenem, against ESBL-producing
organisms [6,7]. However, the ease of once daily dosing
and reduced cost of ETP at $27.67/day vs. $60–$71/day
for IPM and MEM make this drug a desired alternative in
the treatment of the war wounded, especially those requir-
ing a prolonged treatment course (Amerisource Bergen,
Cardinal Health, Federal Supply Schedule drug prices).
The aim of this project is to evaluate ETP susceptibility of
ESBL-producing E. coli and K. pneumoniae clinical isolates.
A secondary aim is to compare IPM and ETP susceptibili-
ties to determine if IPM can be used as a surrogate for ETP
susceptibility.
Methods
All isolates are culled from prior 2005–2006 clinical spec-
imens. Organism identification, screening for ESBL pro-
duction, and antimicrobial susceptibility testing are
performed using Vitek Legacy (bioMerieux, Durham,
NC). Isolates flagged by Vitek as possible ESBL producers
are submitted for disk diffusion confirmatory testing. Phe-
notypic confirmatory disk diffusion testing is done on
presumptive ESBL-producing organisms in accordance
with the Clinical and Laboratory Standards Institute [8].
ETP susceptibility is determined using the epsilometer (E-
test) [AB Biodisk, Solna, Sweden] method as per manufac-
turer's protocol [9]. Briefly, isolates are revived from
freezer stocks by passing twice to 5% Sheep Blood Agar
plates (Remel, Lenexa, KS). Select isolated colonies pro-
duce a 0.5 McFarland suspension in sterile saline. This
suspension is inoculated onto Mueller-Hinton agar plates
which the antibiotic E-test strip was placed. Each ETP E-
test strip consists of a predefined gradient of antibiotic
allowing Minimum Inhibitory Concentration (MIC)
measurements through the range of 0.002–32 ug/mL.
MIC's for each isolate are determined by reading the value
at the point of intersection between the zone of inhibition
edge and the E-test strip.
Susceptibility data to ETP is determined as per the Clinical
and Laboratory Standards Institute interpretive criteria
(4). For ETP, sensitive is defined as MIC</= 2 ug/mL,
intermediate 4 ug/mL, and resistant >/= 8 ug/mL. Data
compiled for 100 clinical isolates (n = 34 E. coli and n =
66 K. pneumoniae) includes specimen site for each isolate
(Figure 1).
Results
100% of ESBL-producing clinical isolates show suscepti-
bility to ETP as per CLSI criteria. ETP MICs range from
0.006 ug/mL to 0.5 ug/mL (mean 0.073, SD 0.093) [95%
CI 0.032 ug/mL] for E. coli. and 0.006 ug/mL to 2 ug/mL
(mean 0.125, SD 0.291) [95% CI 0.070] for K. pneumo-
niae.
100% of isolates susceptible to ETP are also susceptible to
IPM by Vitek (MIC </= 4). In regards to susceptibility of
ESBL-producing organisms to other antibiotics, 21% of
ESBL E. coli and 27% of ESBL K. pneumoniae are suscepti-
ble to a quinolone such as levofloxacin. ESBL E. coli and
K. pneumoniae are 97% and 88% sensitive to amikacin
(aminoglycoside) respectively. Cephalosporin sensitivity
shows approximately 100% resistance to cefepime and
ceftazidime for all clinical specimens (Figures 2 and 3).
Discussion
100% of the clinical isolates of ESBL-producing E. coli and
K. pneumoniae tested were susceptible to ertapenem in this
study with MICs ranging from 0.006 to 0.5 ug/mL for E.
coli and 0.006 to 2 ug/mL for K. pneumoniae. Prior studies
showed similar ETP efficacy for ESBL-producing organ-
isms in vitro [6,7].
Specimen location for ESBL isolatesFigure 1
Specimen location for ESBL isolates. The symbol (*) includes wounds and sterile body fluids and the symbol (**) includes fluid 
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isolates. Livermore et al. tested 181 ESBL-producing clini-
cal Enterobacteriaceae isolates (all Klebsiella spp.) taken
from ICU patients and found ertapenem to inhibit 90% of
isolates but was found to be less active against ESBL non-
producers [7]. Betriu et al. tested 70 clinical ESBL-produc-
ing Enterobacteriaceae isolates which were found to be
98.6% susceptible to ertapenem at 104 and 106 inoculum
with MICs ranging from 0.03–0.12 mg/L [6]. In our study,
inoculum size is held constant and plays no role in evalu-
ation of ETP susceptibility, so no inferences can be made
based on inoculum size.
Susceptibility of ESBL-producing isolates in this study dif-
fered in regards to aminoglycoside and quinolone sensi-
tivity. Overall, greater than 80% of the clinical isolates
show sensitivity to amikacin, while less than 30% are sen-
sitive to levofloxacin suggesting that aminoglycosides
may be appropriate empiric adjunct therapy if concern
over ESBL-producing organisms exist in the critically ill
patient. Our data in conjunction with other studies sug-
gest that ETP may be an alternative to other carbapenems
in the treatment of infections caused by ESBL-producing
organisms. Ertapenem use to treat these infections would
offer the benefit of ease of administration with once daily
dosing (t1/2 4–4.5 hrs) and reduced cost. These advantages
to the use of ETP are of particular value to clinicians and
patients at Walter Reed Army Medical Center due to the
role of ESBL-producing organisms in infections such as
osteomyelitis which require a prolonged course of antibi-
otics. This is of importance because current use of mero-
penem and imipenem to treat these infections with their
burdensome multiple daily dosing regimens often results
in anger and frustration in our outpatient soldiers.
All isolates tested are susceptible to ertapenem and imi-
penem, which has also been observed in prior studies
[6,7]. However, due to lack of resistant isolates, we are
unable to confidently conclude whether IPM susceptibil-
ity could accurately predict ETP susceptibility.
ESBL E.coli susceptibilities to ertapenem and other antibioticsFigure 2
ESBL E.coli susceptibilities to ertapenem and other antibiotics. Solid black represents percentage of isolates sensitive to antibi-
otics. Light gray represents percentage of isolates intermediately sensitive to antibiotics. Diagonal lines represent percentage of 
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should be exercised with caution in light of reports of
recent ETP resistance both in vivo and in vitro to ESBL-pro-
ducing E. coli and K. pneumoniae [10-13]. The maximum
ETP MIC of 2 ug/ml was seen in a Klebsiella pneumoniae
clinical isolate with corresponding MIC to IPM <4 ug/ml.
It has been noted in multiple studies that increasing MIC
of ETP typically corresponds with increased MIC of IPM/
MEM (especially MIC 4–8, intermediate susceptibility
range for IPM/MEM). In a report by Lartigue, ETP resist-
ance (MIC>256 mg/L) shown in ESBL E.coli was associ-
ated with intermediate resistance (MIC 8 mg/L for IPM/
MEM) emphasizing the greater likelihood of resistance
developing to ETP than to other carbapenems [12]. Pater-
son et al. report in vivo resistance to ESBL K. pneumoniae in
which 10.9% of ESBL K. pneumoniae isolates collected
from intra-abdominal sources worldwide were resistant to
ETP [13]. After producing organisms deficient in outer
membrane proteins or porins, Omp 35 and Omp 36,
Jacoby et al. demonstrated in vitro resistance of ESBL K.
pneumoniae to ETP [11]. A similar mechanism of in vivo
resistance involving lack of outer membrane proteins has
recently been reported by Lartigue et al. for ESBL E. coli
from a peritoneal fluid culture [12].
Weaknesses of this study include unknown inoculum
effect, lack of non-ESBL-producing controls, and theoreti-
cally, interobserver variability in interpretation of ETP E-
test sensitivity data. Strengths include the large number of
diverse isolates culled from various clinical sources for
susceptibility testing.
It is difficult to extrapolate in vitro data to clinical practice.
Although in vitro studies show ETP is promising in the
treatment of ESBL organisms, further clinical studies are
necessary. However, ETP should be kept in mind when
ESBL K. pneumoniae susceptibilities to ertapenem and other antibioticsFigure 3
ESBL K. pneumoniae susceptibilities to ertapenem and other antibiotics. Solid black represents percentage of isolates sensitive 
to antibiotics. Light gray represents percentage of isolates intermediately sensitive to antibiotics. Diagonal lines represent per-
centage of isolates resistant to antibiotics.Page 4 of 5
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seeking a safe, effective, easy outpatient antibiotic regi-
men for the treatment of the complicated infections in our
war wounded.
Conclusion
The results of our data show that ESBL Klebsiella pneumo-
niae and ESBL Escherichia coli isolates clinical isolates
culled from soldiers at WRAMC showed uniform ertap-
enem susceptibility. However, recent reports have also
shown increasing ertapenem resistance of ESBL isolates.
This suggests that ertapenem, with its ease of dosing and
improved cost, may be an acceptable alternative to other
carbapenems in the treatment of serious infections, but
should be used with caution after further susceptibility
testing. Clinical trials assessing the use of ertapenem to
treat serious infections caused by ESBL isolates are
needed.
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